Continue to Site

Drug Discovery and Development

FDA advisory panel backs Novavax COVID-19

By |

NovavaxNovavax (Nasdaq:NVAX) has won unanimous backing from the FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) for its NVX-CoV2373 COVID-19 vaccine.

Voting 21 to 0 with one abstention, the VRBPAC recommended that FDA grant emergency use authorization (EUA) to the vaccine for adults 18 and older.

The Novavax would be the fourth vaccine to win authorization in the U.S., following the vaccines from Johnson & Johnson, Moderna, and Pfizer and its partner BioNTech.

The vaccine is likely to win authorization by June, estimated M. Nielsen Hobbs, an analyst for Informa Pharma Intelligence.

While several companies are reading next-generation COVID-19 vaccines, the Novavax vaccine is “not so much a new entrant as a much delayed initial entrant as part of Operation Warp Speed,” Hobbs said.

If it wins authorization, the Novavax vaccine would be the first protein-based COVID-19 vaccine in the U.S.

Earlier this week, FDA released a briefing document noting that it had some concerns related to the Novavax vaccine’s potential to cause myocarditis. In a statement, Novavax downplayed those concerns, pointing to balanced rates of myocarditis between placebo and vaccine recipients in clinical studies.

At present, roughly 30% of Americans remain unvaccinated.

Demand has fallen for the Johnson & Johnson vaccine after federal authorities have recommended constraining its use.

While the NVX-CoV2373 vaccine is protein-based and thus has a similar profile to traditional vaccines for influenza, hepatitis B, shingles and other diseases, it remains unclear how much demand there will be for the new vaccine.

As COVID-19 vaccines and boosters have become available to an incrementally larger swath of the population, the demand for the shots has fallen. “With each new iteration, whether via the third dose or the first inoculations in teens and younger kids, a smaller and smaller percentage of people got jabs,” Hobbs said. “There is a population that was inclined to have gotten their initial shots but didn’t come back for their boosters and didn’t vaccinate their kids.”

After Nasdaq temporarily halted trading of NVAX shares today, the company’s stock price was up 20.57% to $57.48.

Filed Under: Infectious Disease, Uncategorized
Tagged With: , , ,
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Tell Us What You Think!

Related Articles Read More >

Search Drug Discovery & Development